Navigation Links
Donors Welcome the Advance Market Commitment's First Long-Term Supply Commitments
Date:4/9/2010

Global Health Progress applauds world’s poorest countries’ ability to access pneumococcal disease vaccines

(PRWEB) April 10, 2010 -- Global Health Progress applauds the governments of Italy, the United Kingdom, Canada, Russia, and Norway and the Bill & Melinda Gates Foundation as they welcome the first long-term agreements made by pharmaceutical firms to provide increased access to medicine by supplying new, affordable vaccines against pneumococcal disease to the world’s poorest countries.

GlaxoSmithKline (GSK) and Pfizer Inc. are the first companies to agree to supply pneumococcal vaccines through the Advance Market Commitment (AMC). These vaccines may be available as early as this year at a fraction of the price charged in industrialized countries.

The AMC was created to stimulate the development, manufacture, and uptake of affordable vaccines that meet the needs of developing countries.

In June 2009, the governments of Italy, the United Kingdom, Canada, the Russian Federation, Norway and the Gates Foundation launched a pilot AMC with a collective US$1.5 billion commitment. In addition, GAVI will help fund the total cost of these vaccines by contributing up to US$ 1.3 billion for the period 2010 to 2015.

Thanks to these financial commitments, pharmaceutical companies have responded to the incentive and committed to supply millions of doses of life-saving vaccines for ten years at an affordable price –an unprecedented achievement – providing increased access to medicine for millions of people. The AMC enables developing country governments to budget and plan for their immunization programs knowing that vaccines will be available in sufficient quantity and at a price they can afford over the long term.

Pneumococcal disease takes the lives of 1.6 million people each year – including up to one million children before their fifth birthday. More than 90 percent of these deaths occur in developing countries, where access to medicine is not always available. Pneumonia, the most common form of serious pneumococcal disease, accounts for one in every four child deaths, making it the leading cause of death among young children. It is estimated that the pilot could save approximately 900,000 lives by 2015 and up to seven million lives by 2030.

Welcome statements and quotes from AMC donors:

Italy: “Finally public and private sectors join forces to fight poverty and disease. Together, we can make a difference”. Giulio Tremonti, Minister of the Economy and Finance.

United Kingdom: International Development Minister, Mike Foster, said:
“Today we have taken an important step forward in harnessing the potential of the pharmaceutical industry. As a result developing countries will be able to better protect the lives of their children at a price that is affordable and over a time frame that will deliver sustainable improvements in global health targets. The UK will continue to champion innovative solutions that deliver more health for less money.”

Canada welcomes this development that can make a significant difference in reducing the death of children under the age of 5. This is an important step that will support Canada’s G8 focus on maternal and infant health as pneumococcal disease is one of the biggest causes of child mortality, particularly in developing countries.

Norway: “We welcome GlaxoSmithKline (GSK) and Pfizer Inc. as AMC-supplier(s) and hope that more suppliers will join in soon, in particular emerging vaccine manufacturers from developing countries.” Paul Fife, Head of Department

The Bill & Melinda Gates Foundation: “The AMC demonstrates how innovative thinking about global markets can save lives in the world’s poorest countries,” said Tachi Yamada, president of the Gates Foundation’s Global Health Program.

More information available online:
AMC Press Release
GAVI Alliance Press Release
GSK Press Release
Pfizer Press Release

About Global Health Progress
The Global Health Progress initiative brings research-based biopharmaceutical companies and global health leaders together to improve health in the developing world. Through meaningful public-private partnerships with others in the field, including policymakers in the developed and developing world, multi-lateral institutions, non-governmental organizations, and academe, we are helping to shape sustainable solutions that improve the health of all people. http://www.globalhealthprogress.org/index.php

###

Read the full story at http://www.prweb.com/releases/Global-Health-Progress/pharmaceuticals/prweb3853794.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Rh-Negative Blood Donors Needed Now
2. Liver donations from living donors increase 42 percent after educational intervention
3. New Study Says Doctors' Offices -- Not the DMV -- Should Be Where Americans Decide to Become Organ Donors
4. Restrictions on Plasma From Female Donors May Need Revisiting
5. Kidneys From Older Donors Suitable for Seniors
6. Kidney Donors Go On to Lead Long, Healthy Lives
7. Aspen Dental Opens 44 New Offices, Welcomes 340,000 New Patients in 2009
8. BMEGateway Celebrates its 20th Anniversary and Welcomes Dr. William Morgan
9. Researchers welcome new multiple sclerosis drug
10. Patient Advocate Foundation Welcomes Former NASCAR Team Executive as New Executive Vice President of National Partnerships
11. Virginia-Based Patient Advocate Foundation Welcomes Former NASCAR Team Executive as New Executive Vice President of National Partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 ... in 2017. Clinicians who participate in APMs are paid for the quality of care ... effort to build a system that delivers better care and one in which clinicians ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the ... needs of over 30 million. Many interviews with Dr. Carol Francis at the Los ... were suppose to prioritize. Interviews provided below. , Among those present was ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have to clear ... when clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s ... Safety Commission for the proper use of snow blowers:, , When ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... Melville, New York (PRWEB) , ... January 19, ... ... state–of-the-art high definition dynamic telemedicine solutions, has recently unveiled impressive transportable capabilities with ... this newly designed product is an extension to RMT technology that delivers HD, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
Breaking Medicine Technology: